Evidence map›Paper›PMID 37510679›Full record

ArticleJournal of clinical medicine2023

Liver Disease Is a Risk Factor for Recurrent Hyperkalemia: A Retrospective Cohort Study.

Rebecca S Ahdoot, Jui-Ting Hsiung, Abiy Agiro, Yasmin G Brahmbhatt, Kerry Cooper, Souhiela Fawaz, Laura Westfall, Kamyar Kalantar-Zadeh, Elani Streja

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rebecca S AhdootDivision of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, University of California Irvine, Irvine, CA 92868, USA.
Jui-Ting HsiungDivision of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, University of California Irvine, Irvine, CA 92868, USA.
Abiy AgiroAstraZeneca, US Evidence, US Medical Affairs, Wilmington, DE 19803, USA.
Yasmin G BrahmbhattAstraZeneca, US Renal, US Medical Affairs, Wilmington, DE 19803, USA.
Kerry CooperAstraZeneca, US Renal, US Medical Affairs, Wilmington, DE 19803, USA.
Souhiela FawazAstraZeneca, US Renal, US Medical Affairs, Wilmington, DE 19803, USA.
Laura WestfallAstraZeneca, US Renal, US Medical Affairs, Wilmington, DE 19803, USA.
Kamyar Kalantar-ZadehVeterans Affairs Long Beach Healthcare System, 5901 East 7th Street, Long Beach, CA 90822, USA.ORCID 0000-0002-8666-0725
Elani StrejaDivision of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, University of California Irvine, Irvine, CA 92868, USA.
AstraZeneca (United States) · USUniversity of California, Irvine · USUniversity of California, Los Angeles · US

Funding

AstraZeneca N/A
6 · The paper itself

Abstract

Liver disease is often associated with dysfunctional potassium homeostasis but is not a well-established risk factor for hyperkalemia. This retrospective cohort study examined the potential relationship between liver disease and recurrent hyperkalemia. Patients with ≥1 serum potassium measurement between January 2004 and December 2018 who experienced hyperkalemia (serum potassium >5.0 mmol/L) were identified from the United States Veterans Affairs database. A competing risk regression model was used to analyze the relationship between patient characteristics and recurrent hyperkalemia. Of 1,493,539 patients with incident hyperkalemia, 71,790 (4.8%) had liver disease (one inpatient or two outpatient records) within 1 year before the index hyperkalemia event. Recurrent hyperkalemia within 1 year after the index event occurred in 234,807 patients (15.7%) overall, 19,518 (27.2%) with liver disease, and 215,289 (15.1%) without liver disease. The risk of recurrent hyperkalemia was significantly increased in patients with liver disease versus those without (subhazard ratio, 1.34; 95% confidence interval, 1.32-1.37;

Indexed as

cirrhosiselectrolyte imbalancehyperkalemiakidney diseaseliver diseasepotassiumrecurrenceretrospective study

Identifiers

PMID37510679
PMCPMC10380673
OpenAlexW4383724496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.